Albuminex Market Report 2026

Albuminex Market Overview

• The Albuminex market growth in the historic period has been driven by established therapeutic role of albumin, increasing liver disease prevalence • Market expansion is supported by growth in chronic disease burden, expansion of specialty hospitals • Growth Driver: Rising Liver Cancer Incidence Driving Growth In The Albuminex Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Albuminex Market?

Albuminex refers to a brand or specific formulation of human albumin, a protein found in blood plasma. Albumin is crucial for maintaining the osmotic pressure of the blood, helping to regulate the balance of fluids in the body. It is used in medical treatments, particularly for conditions involving burns, shock, liver disease, or kidney problems where blood volume and protein levels are critically low. The main types of albuminex include human serum albumin, bovine serum albumin, and recombinant human serum albumin. Human serum albumin is a protein derived from human plasma, crucial for maintaining blood volume and osmotic pressure. It is used for various clinical indications such as hypovolemia, hypoalbuminemia, oncotic pressure regulation, cardiopulmonary bypass surgery, acute respiratory distress syndrome (ARDS), therapeutic plasma exchange (TPE), burn management, sepsis and septic shock, and other, and is distributed through various channels, including hospital pharmacies, retail and specialty pharmacies, and online pharmacies. It is used by hospitals and clinics, the pharmaceutical and biotechnology industries, and research institutes.

What Is The Albuminex Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic disease burden, expansion of specialty hospitals, increasing use in critical care, improved plasma collection networks, rising healthcare expenditure. Major trends in the forecast period include broad clinical use of human albumin products, rising demand in hypovolemia management, increased application in liver and renal disorders, expansion of plasma based therapeutics, growth of hospital based infusion therapies.

Global Albuminex Market Segmentation

1) By Type: Human Serum Albumin, Bovine Serum Albumin, Recombinant Human Serum Albumin 2) By Clinical Indication: Hypovolemia, Hypoalbuminemia, Oncotic Pressure Regulation, Cardiopulmonary Bypass Surgery, Acute Respiratory Distress Syndrome (ARDS), Therapeutic Plasma Exchange (TPE), Burn Management, Sepsis And Septic Shock, Other Clinical Indications 3) By Distribution Channel: Hospital Pharmacies, Retail And Specialty Pharmacies, Online Pharmacies 4) By End User: Hospital And Clinics, Pharmaceutical And Biotechnology Industry, Research Institutes

What Are The Drivers Of The Albuminex Market?

The rise in liver cancer is expected to drive the growth of the albuminex market going forward. Liver cancer is a disease where abnormal liver cell growth, often due to chronic conditions or lifestyle factors, leads to malignant tumors in the liver. Liver cancer cases are rising due to increased risk factors such as chronic hepatitis, obesity, alcohol consumption, and an aging population. Albuminex is required for treating liver cancer to help manage fluid imbalances and maintain oncotic pressure in patients with compromised liver function, preventing complications including ascites and edema. For instance, in July 2024, according to Cancer Research UK, a UK-based cancer research organization, the number of new liver cancer cases is expected to increase from approximately 7,600 annually in 2023-2025 to around 9,700 annually by 2038-2040. Liver cancer incidence rates overall are projected to rise by 6%, reaching 12 cases per 100,000 people per year by 2038-2040. This increase is expected to affect both males and females, though the rise will be slightly higher in females (8%) than in males (4%). By 2038-2040, the incidence rate for females is expected to reach 8 cases per 100,000 annually, while for males, it will be 16 cases per 100,000 per year. Therefore, the rise in liver cancer is driving the growth of the albuminex industry. The increase in pharmaceutical and medicinal research activities is expected to drive the growth of the albuminex market going forward. Pharmaceutical and medicinal research activities involve the systematic study and development of new drugs, treatments, and therapies to advance healthcare and improve disease management. Pharmaceutical and medicinal research activities are increasing due to advancements in technology, growing healthcare needs, and a focus on innovative therapies for complex and rare diseases. Pharmaceutical and medicinal research activities positively impact Albuminex by driving the development of advanced albumin-based therapies, improving manufacturing processes, expanding clinical applications (e.g., drug delivery systems and critical care), and fostering innovations that enhance product efficacy, safety, and market adoption. For instance, in June 2024, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based industry organization representing pharmaceutical companies, reported that in 2023 North America accounted for 53.3% of world pharmaceutical sales compared with 22.7% for Europe. Therefore, the increase in pharmaceutical and medicinal research activities is driving the growth of the albuminex industry. The rising healthcare expenditure is expected to propel the growth of the albuminex market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances albuminex utilization by expanding access to essential plasma-derived therapies, making it easier for hospitals and clinics to manage fluid loss and restore protein levels in critically ill patients. It supports improved treatment capacity through better funding, allowing healthcare systems to adopt advanced therapeutic solutions and strengthen patient care efficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the albuminex industry.

Key Players In The Global Albuminex Market

Major companies operating in the albuminex market are Bio Products Laboratory Limited

Regional Insights

North America was the largest region in the albuminex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Albuminex Market?

The albuminex market consists of sales of albumin concentrates, albumin-based drug delivery systems, albumin-based vaccines and recombinant albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albuminex Market Report 2026?

The albuminex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albuminex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.